Leap Therapeutics Inc
LPTX0.290USD
-0.032-9.83%
Cierre 09/19, 16:00（ET）Cotizaciones retrasadas 15 min
12.01MCap. mercado
PérdidaP/E TTM
Más Datos de Leap Therapeutics Inc Compañía
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-related protein 1 (DKK1) protein. DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. Its second clinical-stage program is FL-301, a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. It also has two preclinical antibody programs, FL-302 and FL-501. FL-302 is a Claudin18.2/CD137 (also known as 4-1BB) bispecific antibody that is in preclinical development. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.
Información de la empresa
Símbolo de cotizaciónLPTX
Nombre de la empresaLeap Therapeutics Inc
Fecha de salida a bolsaJan 24, 2017
Director ejecutivoMr. Douglas E. (Doug) Onsi
Número de empleados52
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 24
Dirección47 Thorndike St, Suite B1-1
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal02141
Teléfono16177140360
Sitio Webhttps://www.leaptx.com/
Símbolo de cotizaciónLPTX
Fecha de salida a bolsaJan 24, 2017
Director ejecutivoMr. Douglas E. (Doug) Onsi
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Douglas E. (Doug) Onsi
Mr. Douglas E. (Doug) Onsi
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
108.28K
+2.01%
Dr. Christopher K. Mirabelli, Ph.D.
Dr. Christopher K. Mirabelli, Ph.D.
Chairman of the Board
Chairman of the Board
23.05K
+10.21%
Ms. Christine Granfield
Ms. Christine Granfield
Vice President, Head - Regulatory Affairs and Quality
Vice President, Head - Regulatory Affairs and Quality
15.90K
--
Dr. Jason Baum, Ph.D.
Dr. Jason Baum, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
15.90K
--
Dr. James H. Cavanaugh, Ph.D.
Dr. James H. Cavanaugh, Ph.D.
Independent Director
Independent Director
214.00
-60.52%
Dr. Richard L. Schilsky, M.D.
Dr. Richard L. Schilsky, M.D.
Independent Director
Independent Director
--
--
Dr. Joseph Loscalzo, M.D., Ph.D.
Dr. Joseph Loscalzo, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. William W. Li, M.D.
Dr. William W. Li, M.D.
Independent Director
Independent Director
--
--
Mr. Christian M. Richard
Mr. Christian M. Richard
Independent Director
Independent Director
--
--
Ms. Patricia (Patty) Martin
Ms. Patricia (Patty) Martin
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Douglas E. (Doug) Onsi
Mr. Douglas E. (Doug) Onsi
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
108.28K
+2.01%
Dr. Christopher K. Mirabelli, Ph.D.
Dr. Christopher K. Mirabelli, Ph.D.
Chairman of the Board
Chairman of the Board
23.05K
+10.21%
Ms. Christine Granfield
Ms. Christine Granfield
Vice President, Head - Regulatory Affairs and Quality
Vice President, Head - Regulatory Affairs and Quality
15.90K
--
Dr. Jason Baum, Ph.D.
Dr. Jason Baum, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
15.90K
--
Dr. James H. Cavanaugh, Ph.D.
Dr. James H. Cavanaugh, Ph.D.
Independent Director
Independent Director
214.00
-60.52%
Dr. Richard L. Schilsky, M.D.
Dr. Richard L. Schilsky, M.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 16 de ago
Actualizado: sáb., 16 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Gilead Sciences Inc
12.84%
683 Capital Management LLC
3.48%
Acadian Asset Management LLC
2.99%
Beigene Ltd
2.93%
The Vanguard Group, Inc.
2.80%
Otro
74.96%
Accionistas
Accionistas
Proporción
Gilead Sciences Inc
12.84%
683 Capital Management LLC
3.48%
Acadian Asset Management LLC
2.99%
Beigene Ltd
2.93%
The Vanguard Group, Inc.
2.80%
Otro
74.96%
Tipos de accionistas
Accionistas
Proporción
Corporation
15.77%
Investment Advisor
12.04%
Investment Advisor/Hedge Fund
4.24%
Hedge Fund
3.90%
Venture Capital
1.72%
Individual Investor
0.58%
Research Firm
0.15%
Bank and Trust
0.01%
Otro
61.59%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
120
18.70M
45.12%
-8.55M
2025Q1
140
18.85M
45.62%
-6.95M
2024Q4
134
21.35M
55.72%
-2.16M
2024Q3
140
20.83M
54.42%
+2.16M
2024Q2
141
20.87M
54.74%
+4.28M
2024Q1
149
9.36M
39.74%
-1.79M
2023Q4
154
7.72M
34.00%
-3.79M
2023Q3
169
9.36M
44.45%
-1.96M
2023Q2
173
10.09M
52.77%
+1.83M
2023Q1
168
6.01M
55.14%
-976.73K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Gilead Sciences Inc
5.32M
12.84%
--
--
Apr 21, 2025
683 Capital Management LLC
1.45M
3.5%
+99.90K
+7.40%
Mar 31, 2025
Acadian Asset Management LLC
1.28M
3.09%
+1.06M
+470.43%
Mar 31, 2025
Beigene Ltd
1.22M
2.93%
+1.22M
--
Oct 31, 2024
The Vanguard Group, Inc.
1.18M
2.84%
-15.38K
-1.29%
Mar 31, 2025
Monaco asset management S.A.M.
1.05M
2.53%
+844.13K
+410.02%
Mar 31, 2025
Simplify Asset Management Inc
950.97K
2.29%
+4.93K
+0.52%
Mar 31, 2025
HealthCare Ventures LLC
697.23K
1.68%
+20.91K
+3.09%
Apr 21, 2025
Key Client Fiduciary Advisors, LLC
388.72K
0.94%
+27.47K
+7.60%
Mar 31, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Fecha
Tipo
Relación
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
